• Users Online: 1104
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 5  |  Issue : 2  |  Page : 27-31

Sulforaphane in experimental hypertension


1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Benghazi, Benghazi, Libya
2 Department of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Saskatoon, Canada

Correspondence Address:
Ali Banigesh
Department of Pharmacology and toxicology, College of Pharmacy, Benghazi University, Benghazi
Libya
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/LIUJ.LIUJ_6_20

Rights and Permissions

Background: Hypertension is defined as a failure to achieve a blood pressure (BP) target – smaller than 140/90 mmHg. The worldwide burden of hypertension has been associated with globally increased rates of death and disability. There is increasing evidence of strong relation between hypertension and oxidative stress, where either increased oxidative stress or depressed antioxidant level may lead to hypertension. Using stroke-prone spontaneously hypertensive rats (SHRSP) rats, previous studies in our laboratory have shown that broccoli sprouts (high in sulforaphane, a phase-2 protein inducer) attenuate BP and inflammation. Objectives: The question this study addressed was whether sulforaphane (a potent phase-2 protein inducer) can attenuate hypertension in the experimental model using the stroke-prone spontaneously hypertensive rats (SHRsp). Materials and Methods: Sulforaphane (LKT Laboratories) or vehicle was orally gavaged to SHRsp or Sprague–Dawley rats (SD) daily for 15 weeks. The body weight and BP were determined weekly, using a standard tail-cuff BP measurement. Tissues such as hearts and kidneys were collected, weighed, and stored under −80°C for further analysis. Results: When compared to BP in SHRsp control rats (179.9 ± 4.32), sulforaphane significantly reduced BP to 157 ± 5.21 (10 μmol/kg body weight), 136.57 ± 1.96 (20 μmol/kg body weight), and 129.33 ± 6.10 (5 μmol/kg body weight), respectively, in SHRsp rats. Conclusion: Administration of sulforaphane, a potent phase-2 enzyme inducer, daily for more than 3 months, significantly improves BP in SHRsp rats, but it did not have any effects on normotensive rats – SD.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed462    
    Printed14    
    Emailed0    
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal